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Background: Several major ESRD-related regulatory and reimbursement changes were introduced in the United
States in 2011. In several large, national datasets, these changes have been associated with decreases in erythropoiesis
stimulating agent (ESA) utilization and hemoglobin concentrations in the ESRD population, as well as an increase in the
use of red blood cell (RBC) transfusions in this population. Our objective was to examine the use of RBC transfusion
before and after the regulatory and reimbursement changes implemented in 2011 in a prevalent population of chronic
dialysis patients in a large national claims database.
Methods: Patients in the Truven Health MarketScan Commercial and Medicare Databases with evidence of chronic
dialysis were selected for the study. The proportion of chronic dialysis patients who received any RBC transfusion and
RBC transfusion event rates per 100 patient-months were calculated in each month from January 1, 2007 to March 31,
2012. The results were analyzed overall and stratified by primary health insurance payer (commercial payer or Medicare).
Results: Overall, the percent of chronic dialysis patients with RBC transfusion and RBC transfusion event rates per 100
patient-months increased between January 2007 and March 2012. When stratified by primary health insurance payer, it
appears that the increase was driven by the primary Medicare insurance population. While the percent of patients with
RBC transfusion and RBC transfusion event rates did not increase in the commercially insured population between 2007
and 2012 they did increase in the primary Medicare insurance population; the majority of the increase occurred in 2011
during the same time frame as the ESRD-related regulatory and reimbursement changes.
Conclusions: The regulatory and reimbursement changes implemented in 2011 may have contributed to an increase
in the use of RBC transfusions in chronic dialysis patients in the MarketScan dataset who were covered by Medicare
plus Medicare supplemental insurance.
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As of the end of 2010, the total treated end-stage renal
disease (ESRD) population reached 594,374 patients in
the United States [1]. Within this population, approxi-
mately 70% were treated with dialysis [1]. Anemia is a
common complication among patients with ESRD [2]
and erythropoiesis stimulating agents (ESAs) have been
widely utilized for anemia management in this popula-
tion over the past two decades [3,4]. Prior to the devel-
opment of ESAs, the treatment options for anemia were
limited to red blood cell (RBC) transfusions, and to a
lesser extent, androgen and iron therapy [5]. In the pre-
ESA era, 10-20% of dialysis patients received at least one
RBC transfusion in a three month period to avoid severe
anemia [6]. However, after the introduction of epoetin
alfa in 1989, the use of RBC transfusion by Medicare-
sponsored dialysis patients declined significantly to less
than 5% with at least one RBC transfusion in a three
month period [6]. The primary registration trials used
for the approval of epoetin alfa demonstrated correction
of anemia and virtual elimination of transfusions (>90%
reduction) in patients treated with ESAs to a mean
hemoglobin (Hb) of 11.7 g/dL (within the target range of
10.7 to 12.7 g/dL) [7]. From 1992 to 2000, the mean
population Hb in prevalent dialysis patients rose from
about 9.8 to 11.2 g/dL while the overall transfusion rate
was halved [8].
Since the introduction of ESAs, several randomized
trials have reported an increased risk of mortality and
major cardiovascular events in pre-dialysis patients with
CKD treated with ESAs [9-11]. The results of the two
earlier trials prompted the US Food and Drug Adminis-
tration (FDA) to issue a black box warning for all ESAs
in March of 2007; the warning recommended that ESAs
be used at the lowest level necessary to prevent RBC
transfusions [12]. The later TREAT trial enrolled moder-
ately anemic, pre-dialysis patients with type 2 diabetes
and CKD and compared treatment with darbepoetin alfa
to Hb of approximately 13 g/dL to placebo. Treatment
with darbepoetin alfa was not found to reduce the risk
of death or major cardiovascular or renal events and was
associated with an increased risk of stroke [11]. As a re-
sult of the accumulation of studies demonstrating that
ESA use is associated with increased risk of adverse
events, in February 2010, the FDA released a drug safety
communication stating that the manufacturers of all
ESAs are required to implement a risk evaluation miti-
gation stragety (REMS). As part of the REMS, the FDA
required that patients must be provided with a printed
medication guide explaining the risks and benefits of
ESAs each time the ESA is dispensed [13].
Several major ESRD-related regulatory and reimburse-
ment changes were introduced in the United States in
2011. First, under the Medicare Prospective PaymentSystem (PPS) for ESRD implemented by the Centers for
Medicare & Medicaid Services (CMS) in January 2011,
reimbursement for dialysis services was bundled to in-
clude formerly separately billable medications (i.e., ESAs,
intravenous iron, active vitamin D, and ESRD-related an-
tibiotics) [14]. Second, also in January 2011, a quality in-
centive program (QIP) was implemented by CMS to
ensure that dialysis facilities maintain a high quality of
care in the context of a cost-constrained payment sys-
tem. The QIP focused on dialysis adequacy and avoid-
ance of anemia (maintaining patients’ Hb < 12 g/dL and
> 10 g/dL). In July 2011, CMS proposed removing the
lower Hb measure (<10 g/dL); this revision was finalized
in the November 2011 CMS Final Rule and effective on
January 1, 2012 [15]. Finally, in June 2011, the ESA label
information was revised, the primary changes being re-
moval of the Hb target range of 10 to 12 g/dL and inclu-
sion of dosing and administration language focused on
reduction or interruption of ESA dosing when Hb con-
centrations approached or exceeded 11 g/dL [7,16].
Associated with the recent regulatory and reimburse-
ment changes just described, ESA doses and Hb concen-
trations in dialysis patients in the US have decreased.
According to the Dialysis Outcomes and Practice Pat-
terns Study (DOPPS) Practice Monitor (DPM), from
August 2010 to December 2012, the percentage of
ESA-treated patients with a Hb concentration < 10 g/dL
increased from 9% to 20% and those with a Hb con-
centration > 12 g/dL decreased from 26% to 9% [17]. In
the Study to Evaluate the Prospective Payment System Im-
pact on Small Dialysis Organizations (STEPPS), in a group
of dialysis patients, it was found that the percent of pa-
tients with a monthly Hb concentration <10 g/dL in-
creased from 12.7% to 16.8% and the percent of patients
with a monthly Hb concentration >12 g/dL decreased
from 28.7% to 18.5% between Q4 2010 and Q2 2011; dur-
ing the same time period, the median cumulative monthly
dose of intravenous epoetin alfa decreased by approxi-
mately 15% [18]. As well as the evidence demonstrating
that Hb concentrations are declining in the US dialysis
population, evidence from several sources suggests that
RBC transfusion rates have increased in this population
since the regulatory and reimbursement changes imple-
mented 2011 [1,18-20].
The objective of the present study was to examine the
proportion receiving RBC transfusion and RBC transfu-
sion rates before and after the regulatory and reimburse-
ment changes implemented in 2011 in a prevalent
population of chronic dialysis patients. In order to ob-
tain adequate information about the magnitude of year-
to-year variation in the utilization of RBC transfusions
prior to the regulatory and reimbursement changes, we
examined data from 2007–2012. Previous reports of re-
cent RBC transfusion rates have focused on patients
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current literature by examining RBC transfusions in a
population of chronic dialysis patients aged 64 and
under with employer-sponsored commercial insurance.
We additionally examined RBC transfusions in a popula-
tion of patients with Medicare insurance plus employer-
sponsored Medicare supplemental insurance.
Methods
Data sources
This retrospective, observational cohort study was con-
ducted using data from the MarketScan® Commercial
Claims and Encounters (Commercial) Database and the
Medicare Supplemental and Coordination of Benefits
(Medicare) Database for the time period of January 1,
2007 to March 31, 2012. These databases are proprietary
databases and are available for licensure for a fee. As the
owner of the databases, Truven Health Analytics uses
these data for analyses for commercial, government and
academic clients. These databases are constructed from
privately insured paid medical and prescription drug
claims. The Commercial Database contains the health
care experiences of privately insured individuals aged 64
and younger and covered under a variety of fee-for-
service, fully capitated, and partially capitated health
plans. It is constructed from claims and enrollment data
provided by >130 large, employer-sponsored health
plans across the United States. Over 37 million individ-
uals are included in the Commercial Database, encom-
passing employees, their spouses, and their dependents.
The Medicare Database contains the claims and enroll-
ment data of approximately three million retirees with
Medicare Supplemental insurance paid for by employers;
both the Medicare-covered portion of payment and the
employer-paid portion are included in the database. Both
databases provide detailed cost, use, and outcomes data
for healthcare services performed in both inpatient and
outpatient settings as well as outpatient prescription
drug claims. Medical claims are linked to prescription
drug claims and enrollment data through unique enrol-
lee identifiers. All database records are de-identified and
fully compliant with US patient confidentiality require-
ments set forth in the Health Insurance Portability and
Accountability Act (HIPAA).
For patients under 65 years of age, eligibility for Medi-
care coverage for ESRD-related services does not begin
until the fourth month of hemodialysis treatment (or the
first month for home dialysis with appropriate training).
Additionally, after becoming eligible for Medicare, pa-
tients with existing employer-sponsored health insurance
must undergo a 30-month “coordination period” during
which time the employer is designated the primary payer
and Medicare the secondary payer for healthcare ser-
vices. It is only after this 30-month coordination periodthat Medicare assumes responsibility as the primary
payer for healthcare services. In the MarketScan Data-
bases, an individual does not appear in the Medicare
database until the data-contributing employer indicates
that the employee/dependent is eligible for Medicare
coverage (i.e., Medicare coverage status is not independ-
ently verified). It is likely that employers do not indicate
that an employee/dependent is eligible for Medicare
until Medicare becomes the primary health insurance
payer. Therefore, it is likely that the majority of patients
who are eligible for Medicare coverage but still in the
30-month coordination period appear in the Commer-
cial database.
Study population
All patients in the Commercial and Medicare Databases
with evidence of chronic dialysis between January 1,
2007 and March 31, 2012 were selected for the study.
Chronic dialysis was defined as three consecutive calen-
dar months containing at least one medical claim with a
code specific to reimbursement for chronic dialysis or
for chronic dialysis-related procedures and services (see
Additional file 1 for chronic dialysis codes). For the
base-case analysis, the index date was the date of the
first dialysis claim that occurred in the first of the three
consecutive months of dialysis claims. Patients were
additionally required to have dialysis claims in at least
70 percent of the calendar months between the index
date and the end of the follow-up period. The variable
duration follow-up period ended with the earliest of the
end of continuous health plan enrollment, the end of the
study period (March 31, 2012), inpatient deatha, or kid-
ney transplant (see Additional file 2 for kidney trans-
plant codes). These selection criteria are consistent with
the methodology used to identify chronic dialysis pa-
tients by the United States Renal Data System (USRDS)
[1]. In addition to the USRDS criteria, patients were re-
quired to be at least 18 years of age on the index date
and to have at least 180 days of continuous enrollment
before and 90 days of continuous enrollment after the
index date. Consistent with Ibrahim and colleagues [8],
patients were excluded from the analysis if they had evi-
dence of cancer, a hematological condition, or a blood
dyscrasia during the 180-day pre-index period (see
Additional file 3 for codes). The purpose of these exclu-
sions was to eliminate patients who may have received
blood transfusions to treat conditions other than ESRD.
Two sensitivity analyses that evaluated the robustness
of the base-case definition of the chronic dialysis popula-
tion were performed; one used a different index date
and a second used a different set of patient selection
criteria. In the first sensitivity analysis (SA1), the patient
selection criteria were identical to those used in the
base-case analysis, except that the index date was the
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consecutive months of dialysis claims. In a second sensi-
tivity analysis (SA2), an alternative method for identifying
chronic dialysis patients consistent with Gitlin et al. was
used [21]. Chronic dialysis patients were defined as pa-
tients at least 18 years old and with at least two medical
claims with a chronic dialysis code (see Additional file 1
for chronic dialysis codes) at least 30 but no greater than
365 days apart. The set of dialysis codes used in SA2 was
narrower than the set of codes used to identify dialysis in
the main analysis and in SA1; specifically, the codes were
the monthly capitation payment and composite rate codes
specific to reimbursement for chronic dialysis.
Outcomes
Patient characteristics
Health insurance enrollment information as of the index
date was used to determine patients’ age, gender, geo-
graphic region of residence, residence in an urban area,
health insurance plan type, and primary health insurance
payer (commercial payer or Medicare). Dialysis modality
(hemodialysis, peritoneal dialysis, or unknown) was also
determined on the index dialysis claim (see Additional
file 1 for dialysis type codes) as was the year of the index
date. Inpatient and outpatient medical claims from the
180-day period prior to the index date were examined
for the presence of International Classification of Dis-
ease, Ninth Revision, Clinical Modification (ICD-9-CM)
diagnosis codes indicating specific co-morbid conditions.
Claims incurred during the 180-day pre-index period
were also used to calculate the Charlson comorbidity
index (CCI) with Deyo modifications [22,23]. The num-
ber of hospitalizations and the total number of hospital-
ized days that occurred during the pre-index period
were also recorded.
RBC transfusions
The proportion of chronic dialysis patients who received
any RBC transfusion and RBC transfusion event rates
per 100 patient-months were calculated in each month
from January 1, 2007 to March 31, 2012. Only patients
with health plan enrollment for the full month being re-
ported were included in the calculations. Patients who
transitioned from the Commercial Database to the
Medicare Database during the study period contributed
data to the commercial rates if enrolled in the Commer-
cial Database for the full month and to the Medicare
rates if enrolled in the Medicare Database for the full
month. RBC transfusions were identified using ICD-9-
CM diagnosis and procedure codes, Healthcare Com-
mon Procedure Coding System (HCPCS) codes, Current
Procedure and Terminology (CPT-4) codes, and revenue
codes (see Additional file 4 for RBC transfusion codes)
on medical claims incurred during the follow-up period.Because some patients had multiple RBC transfusion
claims within a short time frame and it was not possible
to ascertain whether these claims were associated with a
single RBC transfusion or multiple RBC transfusions
that occurred in rapid succession, we combined individ-
ual transfusion claims within three days of one another
into a transfusion episode, which was the unit of obser-
vation for this study (for details, see [21]). Monthly pro-
portions of chronic dialysis patients receiving RBC
transfusion and RBC transfusion event rates per 100
patient-months were measured overall and were strati-
fied by primary health insurance payer (primary com-
mercial or primary Medicare insurance).
Statistical analyses
For patient baseline characteristics, means and standard
deviations were computed for continuous variables and
frequencies and percentages were calculated for categor-
ical variables. Baseline characteristics were computed
across all chronic dialysis patients who met the study in-
clusion criteria and also calculated separately for chronic
dialysis patients with and without RBC transfusion dur-
ing the follow-up period.
The proportion of patients receiving RBC transfusion
as well as RBC transfusion event rates per 100 patient-
months were estimated by month overall and stratified
by payer and RBC transfusion setting. The monthly pro-
portion of patients receiving RBC transfusion was calcu-
lated as the total number of patients receiving at least
one RBC transfusion during the month divided by the
number of chronic dialysis patients with health plan en-
rollment for the full month. The RBC transfusion rate
per 100 patient-months was also assessed over each
month and was calculated as the total number of RBC
transfusion episodes during the month divided by the
total person-days accumulated during the month multi-
plied by 30 and then by 100.
The formula used for the event rate calculation is
shown below:
Transfusion event ratei ¼ Total# of Transfusion EpisodesiTotal# Chronic Dialysis Patient Daysi
 30 100
where i represents a specific month.
Results
Study sample
Between January 1, 2007 and March 31, 2012 there were
177,327 patients in the MarketScan Commercial and
Medicare Databases with at least one dialysis claim
(Figure 1). After application of the remaining criteria for
inclusion in the base-case analysis, there were 42,790 in-
dividuals who qualified as chronic dialysis patients. In
this sample of chronic dialysis patients, 24,325 (56.8%)
Patients in the MarketScan® Commercial and Medicare Databases with ≥1 
dialysis claim from January 1, 2007 to March 31, 2012 
N = 177,327 (100%)
≥3 consecutive calendar months with ≥1 dialysis claim. Index date = 1st
dialysis event in the 1st month of ≥ 3 consecutive months of dialysis events.
N = 98,185 (55.4%)
≥90 days of post-index continuous enrollment 
N = 93,166 (52.5%)
≥18 years old on the index date 
N = 92,617 (52.2%)
≥180 days of pre-index continuous enrollment
N = 54,125 (30.5%)
Did not have a kidney transplant, cancer, hematological condition, or blood 
dyscrasia during the pre-index period
N = 47,236 (26.6%)
≥1 dialysis claim in ≥70% of calendar months after the index date
N = 42,790 (24.1%)
Commercial insurance at index
N = 24,325 (56.8%)
Medicare at index
N = 18,465 (43.2%)
≥1RBC transfusion during follow-up
N = 8,646 (35.5%) 
≥1 RBC transfusion during follow-up
N = 5,305 (28.7%) 
Figure 1 Selection of chronic dialysis patients, base-case analysis.
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had primary Medicare insurance on the index date.b
Among the chronic dialysis patients with commercial in-
surance, 8,646 (35.5%) had at least one RBC transfusion
during the variable duration follow-up period. In the
sample of patients with primary Medicare insurance,
5,305 (28.7%) had at least one RBC transfusion during
the follow-up period. As the outcome of interest in the
present study is RBC transfusion, in the discussion that
follows, we present the demographic and clinical charac-
teristics of the transfused cohorts only.
The demographic, clinical, and treatment characteris-
tics of chronic dialysis patients with at least one RBCtransfusion who were included in the base-case analysis
are shown in Additional files 5 and 6 stratified by payer
on the index date (commercial: n = 8,646; Medicare: n =
5,305). The average age of patients was 52.1 years (SD =
10.0 years) in the primary commercial insurance sample
and 74.7 years (SD = 7.5 years) in the primary Medicare
insurance sample, consistent with the expectation that
Medicare patients are mostly over age 65 while commer-
cial patients are all under age 65. Four out of ten of the
commercially insured patients (44.3%) and the Medicare
patients (44.0%) were female.
As shown in Additional file 6, during the six-month
pre-index period, the three most common comorbid
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surance and primary Medicare insurance chronic dialysis
populations were hypertension (commercial: 66.5%, n =
5,753; Medicare: 66.7%, n = 3,536), diabetes (commercial:
51.9%%, n = 4,483; Medicare: 51.5%, n = 2,731), and cor-
onary artery disease (commercial: 24.5%, n = 2,117;
Medicare: 40.8%, n = 2,164). The Medicare insurance
population had higher rates of most of the cardiovascu-
lar comorbidities measured (i.e., coronary artery disease,
congestive heart failure, dysrhythmia, cerebrovascular
accident/transient ischemic attack) than did the com-
mercially insured population. The mean Charlson co-
morbidity score was 3.3 (SD = 2.2) in the primary
commercial insurance population and 3.5 (SD = 2.0) in
the primary Medicare insurance population. During the
pre-index period, 38.3% (n = 3,314) of the primary com-
mercial insurance sample and 39.4% (n = 2,090) of the
primary Medicare insurance population experienced at
least one hospitalization.
On the index date, approximately 70% of patients in
both the primary commercial insurance and primary
Medicare insurance samples received hemodialysis and
the remaining patients received either peritoneal dialysis
or dialysis via an unknown modality (Additional file 5).
As shown in Additional file 6, the mean duration of
follow-up was 645.5 days (SD = 476.9 days) for primary
commercial insurance patients and 677.4 days (SD =
509.1 days) for primary Medicare insurance patients.
During the follow-up period, 88.1% (n = 7,617) of pri-
mary commercial insurance patients and 86.4% (n =
4,585) of primary Medicare insurance patients had at
least one inpatient transfusion and 25.7% (n = 2,223) of
primary commercial insurance patients and 26.8% (n =
1,421) of primary Medicare insurance patients had at































Figure 2 Monthly percent of chronic dialysis patients with RBC transf
Base Case: USRDS definition of chronic dialysis, index date =month 1. SA1: se
month 3. SA2: sensitivity analysis #2; alternative definition of chronic dialysis [1Monthly proportions of chronic dialysis patients with RBC
transfusion and RBC transfusion event rates
Figure 2 depicts the proportions of patients with RBC
transfusion by month across the three different methods
(base-case, SA1, and SA2) used to define the chronic
dialysis population. The overall proportions of patients
with RBC transfusion differed in magnitude across the
three methods; however, the trends over time were con-
sistent among the three definitions. A similar pattern
was found among the three different methods in the
monthly RBC transfusion event rates per 100 patient-
months (see Additional file 7). The remainder of this
discussion will therefore focus on the results gener-
ated in the base-case population of chronic dialysis
patients.
As depicted in Figure 2, in the base-case population
overall, the proportion of patients with RBC transfusion
increased from January 2007 to March 2012. The per-
cent of patients with at least one RBC transfusion was
2.4% in January of 2007, 3.0% in January of 2009, 3.2% in
January of 2011, and 3.4% in January of 2012. Similarly,
the RBC transfusion event rate per 100 patient-months
increased from 2.6 in January of 2007 to 3.2 in January
of 2009 to 3.3 in January of 2011 and to 3.6 in January
of 2012 (see Additional file 7).
Figure 3 depicts the monthly proportions of patients
with RBC transfusion separately for the primary com-
mercial insurance and primary Medicare insurance pop-
ulations (see Additional file 8 for the monthly RBC
transfusion event rates per 100 patient-months stratified
by primary insurance payer). In each year of the study, a
higher proportion of the patients with primary commer-
cial insurance than with primary Medicare insurance
received RBC transfusion. Patients with primary com-
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Figure 3 Monthly percent of chronic dialysis patients with RBC transfusion, base case population stratified by payer.
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care insurance overall (see Additional file 8).
While the upward trend in the monthly proportions of
patients with RBC transfusion and RBC transfusion
event rates that was observed from January 2007 to
March 2012 overall (Figure 2, Additional file 7) was pro-
nounced in the primary Medicare insurance population
the upward trend was not observed in the primary com-
mercial insurance population (Figure 3, Additional file 8).
Figures 4 and 5 depict the monthly proportions of pa-
tients with RBC transfusion separately for the primary
commercial insurance and primary Medicare insurance
populations stratified by calendar year (see Additional
files 9 and 10 for the RBC transfusion event rates per
100 patient-months separately for the primary com-
mercial insurance and primary Medicare insurance pop-
ulations stratified by calendar year). In the primary






































Figure 4 Percent of Medicare chronic dialysis patients with RBC transproportions of patients with RBC transfusion and RBC
transfusion event rates were similar in 2009 and 2010,
the proportions and rates were higher in 2011, especially
beginning in June-July 2011, (Figure 4, Additional file 9).
This pattern of results was not evident in the primary
commercial insurance population; rather, the proportion
of patients with RBC transfusion and the RBC transfu-
sion event rates remained consistent from 2009–2012 in
this population (Figure 5, Additional file 10).
Discussion
This retrospective study was conducted in a population
of chronic dialysis patients with employer-sponsored
health insurance or Medicare insurance with employer-
sponsored Medicare supplemental insurance identified
from the Truven Health MarketScan Research Data-
bases. Consistent with the findings in the USRDS Medi-

















































Figure 5 Percent of commercial chronic dialysis patients with RBC transfusion, base case population stratified by year.
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with an increase in the proportion of chronic dialysis pa-
tients with RBC transfusion in the Medicare population.
In the primary Medicare insurance population, while the
monthly proportions of patients with RBC transfusion
and RBC transfusion rates were similar in 2009 and 2010,
the proportions and rates were higher in 2011, especially
beginning in June-July 2011 (Figure 4, Additional file 9)
suggesting that the increase in use of RBC transfusion in
chronic dialysis patients may have been related to the
regulatory and reimbursement changes implemented in
2011. This pattern of results was not evident in the
primary commercial insurance population (Figure 5,
Additional file 10); rather, the proportion of patients with
RBC transfusion and the RBC transfusion event rates
remained consistent from 2009–2012 in this population.
The fact that the 2011 increase in RBC transfusion use
was not evident in the commercially insured population
suggests that the changes in RBC transfusion utilization
may have been more directly related to the CMS regula-
tory changes, which applied only to the Medicare popula-
tion, than to the ESA label changes, which applied to both
the commercial and Medicare populations.
Our finding of higher transfusion rates in the commer-
cially insured population as compared to the Medicare
population was counterintuitive. One might expect that
transfusion rates would be lower in a population of
younger, healthier patients; the patient demographic and
clinical characteristics presented in Additional files 5
and 6 indicate that the commercially insured patients
were 22.6 years younger on average and had lower rates
of most of the baseline comorbidities measured, espe-
cially the cardiovascular comorbidities. To the best of
our knowledge, there are no other published data on
RBC transfusion rates for primarily commercially in-
sured chronic dialysis patients; therefore, we have nocontext in which to place the findings presented here.
However, we have several hypotheses regarding our
counterintuitive finding. First, while the commercially
insured population may have appeared healthier than
the Medicare population with respect to the comorbidi-
ties that were measured, it is possible that the com-
mercially insured patients were in fact a less healthy
population along dimensions that were not measured.
Second, there may be systematic differences between the
commercially and Medicare insured populations that im-
pact the treatments that physicians are likely to recom-
mend. For example, the Medicare insured patients had
higher rates of cardiovascular comorbidities than their
commercially insured counterparts; given the risk of ad-
verse cardiovascular events (e.g., transfusion associated
circulatory overload) associated with RBC transfusions,
perhaps physicians are less likely to prescribe RBC trans-
fusion to patients with cardiovascular comorbidities.
Finally, it is possible that transfusion rates were underes-
timated in the Medicare sample for transfusions that
took place during hospital re-admissions within 60 days
after an inpatient admission. Medicare beneficiaries are
only responsible for a Part A deductible for each benefit
period. A benefit period begins on the admission date
and ends when the beneficiary has not received any in-
patient hospital care for 60 consecutive days. Any subse-
quent inpatient claims incurred before this time do not
appear in the Medicare database because there is no pa-
tient responsibility for payment; therefore, re-admissions
that occur within this 60 day window are not captured.
Because the present study was not designed to measure
or control for differences between the commercially in-
sured and Medicare populations, we are unable to pro-
vide any definitive explanation for our counterintuitive
finding; this question can be addressed in future re-
search. However, because we are the first to report RBC
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a gap in the literature.
In contrast, our findings in the Medicare population
were consistent with previous reports. The post-January
2011 rise in the proportions of dialysis patients with
RBC transfusion observed in the MarketScan primary
Medicare insurance population has been observed in
several other national datasets. In the USRDS dataset,
which consists of a population of prevalent dialysis pa-
tients with Medicare insurance, while the transfusion
rate per 100 patient months remained steady prior to
the regulatory and reimbursement changes at approxi-
mately 2.5 throughout 2009 and most of 2010, they
began to increase in October to November of 2010 and
had increased to over 3.0 by November 2011 [19]. A
2011 rise in the proportion of chronic dialysis patients
with at least one RBC transfusion per month was also
observed in the population of patients with hospital-
based transfusions identified the DOPPS population
[20]. However, in the DOPPS population, the rise in the
proportion of dialysis patients with transfusion occurred
mainly between January 2011 (2.6%) and May 2011 (6.9%),
whereas in the present MarketScan dataset, the rise in the
primary Medicare insurance population occurred between
May (2.1%) and December (3.4%) [24]. Finally, an increase
in the proportion of patients with transfusion was also ob-
served in the Study to Evaluate the Prospective Payment
System Impact on Small Dialysis Organizations (STEPPS).
The authors of this study reported that the proportion of
prevalent dialysis patients with at least one transfusion in
a calendar quarter increased from 1.8% in Q4 2010 to
2.9% in Q2 2011 [18].
An increase in the use of RBC transfusions in the
chronic dialysis population may result in an associated
increase in transfusion-related complications, such as
hemolytic and non-hemolytic transfusion reactions, infec-
tions, transfusion-related acute lung injury, transfusion-
associated circulatory overload, and hyperkalemia [25-28].
In previous work, we showed that while infrequent, pay-
ments for RBC transfusion complications were very high
when complications occurred; mean payments for com-
plications ranged from $213 (SD = $168) for delayed
hemolytic transfusion reactions to $19,466 (SD = $15,424)
for congestive heart failure [21]. Additionally, RBC trans-
fusions can result in sensitization to human leukocyte
antigen (HLA), which reduces the opportunity for future
kidney transplantation [29]. However, the risk of adverse
cardiovascular events associated with ESA treatment
should also be considered when determining the appropri-
ate anemia management strategy for chronic dialysis pa-
tients [9-11]. The potential for high-cost complications
associated with RBC transfusion as well as the high cost of
adverse events associated with ESA use should be consid-
ered by policy makers when determining the appropriatereimbursement policy for chronic dialysis patients. At
present, the hemoglobin level at which the risk of adverse
events in anemic CKD patients (with or without dialysis)
treated with ESAs increases is unknown [30]. This is an
important gap in knowledge that, when addressed, will
better enable clinicians and policy makers to weigh the
costs and benefits of the various anemia management
options.
Our study had several limitations. Patients in our sam-
ple had either commercial insurance or commercial plus
Medicare supplemental insurance as their primary cover-
age and therefore, these results may not be generalizable
to patients who are uninsured, are covered only by Medi-
care, or have other types of insurance coverage. Patient
clinical characteristics, dialysis services, and RBC transfu-
sions were identified using ICD-9-CM, HCPCS, CPT, and
revenue codes as recorded on administrative claims. It is
possible that incomplete, missing, or miscoded claims im-
pacted the study findings; however, coding errors are likely
equally distributed both across time and across the com-
mercially insured and primary Medicare insurance co-
horts. Inclusion in the commercially insured and primary
Medicare insurance samples required at least nine months
(180 pre- and 90 days post-index) of continuous health
plan enrollment. This requirement may have biased the
sample toward a healthier-than-usual subset of the overall
chronic dialysis population. For each patient, all RBC
transfusion claims identified within a three day period
after an initial transfusion claim were combined and de-
fined as a single “transfusion episode”; use of this method-
ology may have resulted in an underestimation of the
transfusion rates. These analyses included all RBC transfu-
sions and did not distinguish between those administered
for treatment of chronic anemia and those administered
in the context of an acute, blood-loss related event. As
discussed above, it is possible that transfusion rates were
underestimated in the Medicare sample for transfusions
that took place during hospital re-admissions within
60 days after an inpatient admission. Information about
Hb levels and ESA utilization was not available for this
population; therefore, we were unable to make direct asso-
ciations between these measures and use of RBC transfu-
sions. We did not measure dialysis vintage, severity of
CKD, or anemia status, and therefore cannot identify
potential differences between the commercially- and
Medicare-insured populations that could potentially help
to explain the differences that we found in the RBC trans-
fusion rates in these two populations. Finally, we observed
an association between the introduction of regulatory and
reimbursement changes and an increase in RBC transfu-
sion rates in 2011 for patients with Medicare supplemen-
tal insurance, but we did not observe the same association
for patients with commercial insurance. It is out of the
scope of this study to determine if the difference in
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insured populations is because the regulatory and reim-
bursement change mainly affects Medicare, or because
Medicare patients had a lower rate to start with due to
their older age (i.e., Medicare patients were 23 years older
than commercial patients in our study), or both. Future
studies will be needed to help address this question.
Conclusions
The regulatory and reimbursement changes implemented
in 2011 may have contributed to an increase in the use of
RBC transfusion in patients covered by Medicare supple-
mental insurance. No increase in RBC transfusion was
found in the commercially insured population. Future re-
search is needed to explain this difference in the Medicare
and Commercial populations. However, the fact that the
2011 increase in RBC transfusion use observed in the pri-
mary Medicare insurance population was not evident in
the commercially insured population suggests that the
changes in RBC transfusion utilization may have been as-
sociated with the CMS regulatory changes, which applied
only to the Medicare population, and not the ESA label
changes, which applied to both the commercial and Medi-
care populations.
Endnotes
aUsing administrative claims data, death is only ob-
servable when recorded as a discharge status on an in-
patient claim. If death occurs outside of the inpatient
setting, it will manifest in the patient’s data as the end of
continuous enrollment.
bFor SA1, 39,387 patients met the study inclusion cri-
teria; 22,340 patients had commercial insurance (56.7%)
and 17,047 (43.3%) had Medicare supplemental insur-
ance on the index date. For SA2, 99,202 patients met the
study inclusion criteria; 57,361 patients had commercial
insurance (57.8%) and 41,841 (42.2%) had Medicare sup-
plemental insurance on the index date.
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